13,600 Shares in MacroGenics, Inc. (NASDAQ:MGNX) Bought by Jump Financial LLC

Jump Financial LLC acquired a new position in shares of MacroGenics, Inc. (NASDAQ:MGNX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,600 shares of the biopharmaceutical company’s stock, valued at approximately $44,000.

Several other large investors have also modified their holdings of the company. XML Financial LLC boosted its holdings in shares of MacroGenics by 31.6% during the 4th quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 5,569 shares during the period. Stifel Financial Corp boosted its holdings in shares of MacroGenics by 19.7% during the 3rd quarter. Stifel Financial Corp now owns 39,888 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 6,578 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of MacroGenics by 45.4% during the 4th quarter. Wells Fargo & Company MN now owns 29,838 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 9,312 shares during the period. American Century Companies Inc. bought a new stake in MacroGenics in the 4th quarter valued at $38,000. Finally, Sanders Morris Harris LLC bought a new stake in MacroGenics in the 4th quarter valued at $40,000. 96.89% of the stock is owned by institutional investors.

MacroGenics Stock Down 4.1 %

Shares of MacroGenics stock opened at $1.64 on Tuesday. The stock has a market capitalization of $103.47 million, a P/E ratio of -1.04 and a beta of 2.23. The company has a 50-day simple moving average of $1.80 and a 200 day simple moving average of $2.81. MacroGenics, Inc. has a 12-month low of $0.99 and a 12-month high of $16.44.

MacroGenics (NASDAQ:MGNX) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The firm had revenue of $49.40 million for the quarter, compared to analyst estimates of $34.17 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. On average, equities analysts anticipate that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. HC Wainwright reduced their price target on shares of MacroGenics from $4.00 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, March 25th. StockNews.com downgraded shares of MacroGenics from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.38.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.